Why Choose EverydayMeds for Your Complete Treatment?
Understanding the Difference Between Ozempic and Wegovy: Licensing and Indications
The fundamental difference between Ozempic and Wegovy lies in their licensed indications, despite both containing the same active ingredient, semaglutide. Ozempic is exclusively licensed for managing type 2 diabetes mellitus and cannot legally be prescribed for weight management purposes in the UK. Wegovy, conversely, is specifically licensed by the MHRA for chronic weight management in adults with a BMI of 30kg/m² or above, or 27kg/m² with weight-related complications such as hypertension or sleep apnoea.
This licensing difference between Ozempic and Wegovy extends to dosing protocols and clinical monitoring requirements. Wegovy follows a structured dose escalation from 0.25mg to a maintenance dose of 2.4mg, designed specifically for weight management alongside a reduced-calorie diet and increased physical activity. At EverydayMeds, we ensure seamless access to every dose in this escalation pathway, eliminating treatment disruption that often occurs when pharmacies stock incomplete ranges.
Complete Wegovy Pricing Structure: All Doses Available
Our comprehensive pricing reflects the full Wegovy dose range, starting with the 0.25mg starter dose at £79.99 for weeks 1-4, progressing through 0.5mg at £94.99 (weeks 5-8), 1mg at £99.99 (weeks 9-12), and 1.7mg at £139.99 (weeks 13-16). The maintenance dose of 2.4mg, used from week 17 onwards, costs £209.99 per pen. New customers benefit from discount code FIRST40 applied at checkout, whilst returning patients use code DOSE25 to reach these final prices.
Understanding the difference between Ozempic and Wegovy pricing is important for budgeting your treatment. Our bundle options provide convenience for patients wanting Reliable Supply continuity, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Ultimate Stability Trio (three 2.4mg pens) for £649.99. These bundles ensure you maintain treatment momentum without supply interruptions that can compromise weight management progress.
Clinical Evidence: STEP Trials Demonstrate Wegovy Efficacy
The difference between Ozempic and Wegovy becomes clear when examining their respective clinical trial programmes. Wegovy's efficacy is established through the comprehensive STEP trial series, with STEP 1 demonstrating an average weight loss of approximately 15% at 68 weeks when used alongside diet and exercise, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 specifically evaluated patients with type 2 diabetes, showing around 9.6% average weight reduction.
Long-term data from STEP 5 indicates that patients taking Wegovy may maintain approximately clinically studied weight loss at two years, whilst the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events. These trials exclusively studied the 2.4mg maintenance dose, highlighting why completing the full dose escalation pathway available through EverydayMeds is essential for optimal outcomes.
Mechanism of Action: How Wegovy Supports Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of naturally occurring incretin hormones that regulate appetite and food intake. Unlike Ozempic's primary focus on glucose control, Wegovy's mechanism specifically targets brain appetite centres to reduce hunger signals and promote satiety after smaller meals. The medication may help decrease food cravings whilst slowing gastric emptying, extending feelings of fullness between meals. This dual action on both central appetite regulation and peripheral digestive processes distinguishes Wegovy's weight management approach. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system ensures consistent therapeutic levels throughout the week, supporting sustained appetite control.
Streamlined Ordering Process: From Assessment to Delivery
Accessing Wegovy through EverydayMeds begins with our 3-minute online clinical assessment, designed to evaluate your suitability for this prescription-only medicine. Our qualified prescribers review applications within three working days as standard, with express 24-hour review available for urgent requirements. Once approved, your medication ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transport to preserve medication integrity. This temperature-controlled logistics system ensures every dose arrives in optimal condition, whether you're starting with 0.25mg or continuing with maintenance 2.4mg injections. Our GPhC-registered pharmacy (#9012878) ensures pharmaceutical-grade storage and handling throughout the supply chain.
Storage Requirements and Practical Considerations
Understanding storage requirements highlights another difference between Ozempic and Wegovy usage patterns in clinical practice. Wegovy pens must be stored in the refrigerator at 2-8°C before first use, but can remain at room temperature below 30°C for up to six weeks once removed from refrigeration, offering superior travel convenience compared to some alternatives. The FlexTouch pen delivery system provides accurate, consistent dosing throughout the escalation schedule, from the initial 0.25mg through to the 2.4mg maintenance dose. Each pen contains four weekly doses, simplifying medication management and reducing injection frequency compared to daily alternatives. The dose escalation protocol cannot be accelerated or modified, making reliable supply of each sequential strength essential for treatment success.
Comprehensive Dose Management: Why Complete Range Availability Matters
The critical difference between Ozempic and Wegovy extends to dose escalation requirements that demand pharmacy reliability and stock consistency. Many patients experience treatment disruption when their pharmacy cannot supply the next dose in the sequence, potentially compromising weight management progress and requiring dose re-escalation. Our comprehensive inventory management ensures immediate availability of every Wegovy strength, from initial 0.25mg starter pens through to long-term 2.4mg maintenance supplies.
This complete dose availability becomes particularly valuable during the transition to maintenance therapy, where consistent 2.4mg supply is essential for sustained weight management. Patients who experience supply interruptions often struggle to maintain their weight loss achievements, making pharmacy reliability a crucial factor in long-term success. EverydayMeds eliminates this risk through proactive inventory management and direct manufacturer relationships.
Expert Clinical Support and Prescription Management
Accessing Wegovy through our GPhC-registered pharmacy (#9012878) ensures proper clinical oversight throughout your weight management journey, distinguishing our service from less regulated alternatives. Our prescribers understand the specific difference between Ozempic and Wegovy indications, ensuring appropriate prescribing aligned with MHRA licensing requirements and NICE guidance TA875. Whether you're starting your first 0.25mg dose or transitioning to 2.4mg maintenance therapy, our clinical team provides ongoing support and monitoring. New customers can begin their assessment immediately using discount code FIRST40, whilst returning patients benefit from code DOSE25 for continued treatment. Visit https://everydaymeds.co.uk/collections/wegovy to start your clinical assessment and secure your complete dose pathway today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
